Table 6. Risk of BCP ALL, non-BCP leukaemia and paediatric solid tumours associated with DPB1 supergenotypes, compared with controls.

	BCP ALL			Non BCP leukaemia			Solid tumour
Supergenotype	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
DP2/DP2 (GEG/GEG)	0.9	0.4–1.9	0.99	0.9	0.3–2.8	0.99	1.02	0.4–2.4	0.99
DP2/DP4 (GEG/GKG)	2.1	1.5–2.9	0.00004*	1.6	0.9–2.7	0.14	1.1	0.7–1.8	0.7
DP2/DP6 (GEG/LED)	2.5	1.0–5.8	0.06	2.5	0.8–7.7	0.3	1.5	0.5–4.5	0.6
DP2/DP3 (GEG/LKD)	1.5	0.7–3.1	0.42	0.8	0.3–3.6	0.99	1.1	0.4–2.8	0.99
DP2/DP8 (GEG/GED)	3.8	0.3–41.7	0.88	12.5	1.1–138.5	0.38	—	—	—
DP2/DP1 (GEG/GKD)	1.1	0.5–2.7	0.96	0.6	0.1–7.9	0.99	0.9	0.3–2.6	0.99
DP4/DP4 (GKG/GKG)	0.9	0.7–1.1	0.40	0.8	0.6–1.1	0.17	1.1	0.9–1.4	0.3
DP4/DP6 (GKG/LED)	1.9	1.2–3.0	0.006	2.7	1.6–4.9	0.002*	1.7	1.0–2.9	0.06
DP4/DP3 (GKG/LKD)	1.1	0.8–1.4	0.80	1.2	1.2–14.6	0.1	1.1	0.7–1.5	0.8
DP4/DP8 (GKG/GED)	2.7	0.9–7.1	0.08	1.9	0.1–15.3	0.99	0.6	0.1–2.9	0.7
DP4/DP1 (GKG/GKD)	0.8	0.6–1.2	0.40	0.9	0.6–2.0	0.8	0.6	0.4–0.9	0.04
DP6/DP6 (LED/LED)	0.6	0.2–1.7	0.48	1.1	0.3–4.0	0.99	1.7	0.7–4.3	0.4
DP6/DP3 (LED/LKD)	0.5	0.2–1.1	0.09	1.1	0.04–3.1	0.67	0.2	0.07–0.81	0.02
DP6/DP8 (LED/GED)	—	—	—	—	—	—	6.3	0.6–70.2	0.6
DP6/DP1 (LED/GKD)	0.8	0.3–2.3	0.89	2.2	0.7–6.7	0.37	0.9	0.3–2.8	0.99
DP3/DP3 (LKD/LKD)	0.7	0.4–1.2	0.23	0.8	0.4–1.8	0.76	1.1	0.6–1.9	0.9
DP3/DP8 (LKD/GED)	3.3	0.8–12.8	0.16	2.5	0.4–15.0	0.95	2.1	0.4–10.5	0.7
DP3/DP1 (LKD/GKD)	0.5	0.2–1.2	0.15	1.6	0.5–3.9	0.85	1.2	0.5–2.7	0.8
DP8/DP8 (GED/GED)	—	—	—	—	—	—	—	—	—
DP8/DP1 (GED/GKD)	3.8	0.3–41.7	0.88	—	—	—	—	—	—
DP1/DP1 (GKD/GKD)	0.2	0.1–0.5	0.00004*	0.4	0.1–1.06	0.06	0.8	0.4–1.5	0.6
Number=	687			208			409

^*Significant (P<0.05) after correction for 21 supergenotypes.